Loading stock data…
Solid Biosciences Inc (SLDB)
$9.47+0.18 (+1.94%)
Market ClosedLast close Jun 29
Solid Biosciences Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Solid Biosciences Inc. in the Healthcare sector is trading at $9.47 with a market capitalization of $689M. Wall Street consensus targets $17.38 (13 analysts), implying a +83.6% move over the next 12 months. The stock is currently near its 52-week high of $9.78, remaining 48.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +83.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$57.31M↓ | -$49.40M↓ | -$48.06M↓ | -$41.69M↓ | -$40.05M |
| Net Income | -$56.74M↓ | -$49.79M↓ | -$45.78M↓ | -$39.48M↓ | -$39.28M |
Peer Comparison
JNJUNHPFE
Fundamentals
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for th...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$689.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-51.26%
Volume
Today's trading volume
1.67M
Recent News
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says
Sarepta Therapeutics' (SRPT) Elevidys for Duchenne muscular dystrophy shows near-term stabilization,
Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?
Solid Biosciences Inc (NASDAQ:SLDB) is one of the best gene therapy stocks to buy in 2026. The stock has been a big win for investors, having gained roughly 75% over the past six months and surged more than 190% over the past 12 months. Analysts expect Solid Biosciences stock to keep going up, predicting that […]
Solid Biosciences says interim results reinforce confidence in SGT-003 potential
Solid Biosciences (SLDB) reported updated “positive” interim data from the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trial of SGT-003. The new data, including additional muscle biopsy, serum biomarker, cardiac function, and safety analyses, “add to a growing dataset that suggests the potential of the biological activity of SGT-003 microdystrophin therapy,” the company stated. The interim update was delivered in an oral presentation at the 2026 MDA Annual Meeting on March 11. “SGT-003 has been
Stock Market Today, March 11: Oracle Surges as Markets Weigh Geopolitical Risks
Today, March 11, 2026, Oracle’s earnings beat and solid inflation data stand out as U.S. stocks wobble on oil and war fears.
Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia Update
Solid Biosciences (NASDAQ:SLDB) used a presentation at the 2026 Emerging Outlook Biotech Summit to outline its gene therapy-focused pipeline and discuss recent regulatory interactions around its lead Duchenne muscular dystrophy (DMD) program, SGT-003, as well as early progress in Friedreich’s ataxia